Novartis launches viral vector production facility in Mengeš
Mengeš, 5 February - Swiss pharma company Novartis has inaugurated a new viral vector production facility in Mengeš north of Ljubljana, its first of this kind in Europe, in an investment valued at EUR 40 million.
Mengeš
A new viral vector production facility of Novartis in Mengeš.
Photo: Bor Slana/STA
Mengeš
A new viral vector production facility of Novartis in Mengeš.
Photo: Bor Slana/STA
Mengeš
A new viral vector production facility of Novartis in Mengeš.
Photo: Bor Slana/STA
The rest of this news item is available to subscribers.
The news item consists of 2.016 characters (without spaces) or 354 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.